Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Self-assembled hyaluronic acid nanoparticles target TLR2 to regulate macrophage M1 polarization and alleviate psoriasis

ABSTRACT: Self-assembled hyaluronic acid nanoparticles (HANPs) possess unique biocompatibility and receptor-binding properties, making them widely studied as drug delivery systems. Notably, empty HANPs alone have demonstrated therapeutic and ameliorative effects in various inflammatory diseases. In this study, we conjugated hyaluronic acid and 5βcholanic acid to create self-assembled nanoparticles (HACNs). We then investigated the effects of HACNs on macrophage polarization towards the pro-inflammatory M1 phenotype using mouse primary bone marrow-derived macrophages and the human monocyte cell line THP-1 cells. Our findings reveal that HACNs directly interact with Toll-like receptor 2 (TLR2) and effectively suppress the expression of pro-inflammatory mediators by competitively inhibiting ligand-receptor interactions in macrophages. This inhibitory effect on TLR2 signaling is mainly due to the spherical structure of the selfassembled hydrophilic hyaluronic acid (HA) shell, rather than to free HA or the hydrophobic core component, 5β-cholanic acid. Furthermore, the protective effects of HACNs against IMQ-induced epidermal hyperplasia and elevated pro-inflammatory cytokine levels were significantly diminished in TLR2-defecient mice. These results highlight the potential of empty HACNs as effective therapeutic agents for TLR2- mediated inflammatory disorders.

ORGANISM(S): Mus musculus

PROVIDER: GSE276941 | GEO | 2025/09/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Self-assembled hyaluronic acid nanoparticles target TLR2 to regulate macrophage M1 polarization and alleviate psoriasis

Project description:Self-assembled hyaluronic acid nanoparticles target TLR2 to regulate macrophage M1 polarization and alleviate psoriasis

| PRJNA1159773 | ENA

Hydrocortisone and Triiodothyronine Regulate Hyaluronate Synthesis in a Tissue–Engineered Human Dermal Equivalent through Independent Pathways

2015-04-08 | GSE56616 | GEO

Crosslinking Proteomics Indicates Effects of Simvastatin on the TLR2 interactome and Reveals ACTR1A as a Novel Regulator of the TLR2 Signal Cascade

Project description:Toll-like receptor 2 (TLR2) is a pattern recognition receptor that, upon ligation by microbial molecules, interacts with other proteins to initiate pro-inflammatory responses by the cell. Statins (hydroxymethylglutaryl coenzyme A reductase inhibitors), drugs widely prescribed to reduce hypercholesterolemia, are reported to have both pro- and anti-inflammatory effects upon cells. Some of these responses are presumed to be driven by effects on signaling proteins at the plasma membrane, but the underlying mechanisms remain obscure. We reasoned that profiling the effect of statins on the repertoire of TLR2-interacting proteins might provide novel insights into the mechanisms by which statins impact inflammation. In order to study the TLR2 interactome, we designed a co-immunoprecipitation (IP)-based cross-linking proteomics study. A hemagglutinin (HA)-tagged-TLR2 transfected HEK293 cell line was utilized to precipitate the TLR2 interactome upon cell exposure to the TLR2 agonist Pam3CSK4 and simvastatin, singly and in combination. To stabilize protein interactors, we utilized two different chemical cross-linkers with different spacer chain lengths. Proteomic analysis revealed important combinatorial effects of simvastatin and Pam3CSK4 on the TLR2 interactome. After stringent data filtering, we identified alpha-centractin (ACTR1A), an actin-related protein and subunit of the dynactin complex, as a potential interactor of TLR2. The interaction was validated using biochemical methods. RNA interference studies revealed an important role for ACTR1A in induction of pro-inflammatory cytokines. Taken together, we report that statins remodel the TLR2 interactome, and we identify ACTR1A, a part of the dynactin complex, as a novel regulator of TLR2-mediated immune signaling pathways.

2019-06-24 | PXD012759 | Pride

Hydrocortisone and Triiodothyronine Regulate Hyaluronate Synthesis in a Tissue–Engineered Human Dermal Equivalent through Independent Pathways

Project description:Hydrocortisone (HC) and triiodothyronine (T3) have both been shown to be capable of independently inhibiting hyaluronate (HA, hyaluronic acid) synthesis in a self-assembled human dermal equivalent (human dermal matrix). We sought to investigate the action of these two hormones in concert on extracellular matrix formation and HA inhibition in a tissue engineered human dermal matrix. RNA preparations were sent to CFG Microarray Core (E). Three replicate samples from each condition were used in the study. The RNA was amplified, labeled, and hybridized to the GLYCOv4 microarrays.

2015-04-08 | E-GEOD-56616 | biostudies-arrayexpress

Impact of hyaluronic acid on cutaneous T-cell lymphoma microenvironment: A novel anti-tumor mechanism of bexarotene

Project description:Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma that primarily affects the skin rich in hyaluronic acid（HA）. HA composes extracellular matrix in the dermis, which likely affects the development of CTCL but is poorly understood. Here, we show that low molecular weight HA (LMWHA) possibly exacerbates CTCL in mouse and human specimens, and bexarotene already being used in CTCL treatment can decrease HA production. Patients’ serum and skin sections showed higher HA expression than healthy controls. HA extracted from the skin of mice inoculated with tumors showed an increase in LMWHA. LMWHA increased lymphoma cell proliferation in vitro and accelerated tumor formation in mice in vivo. LMWHA also created a favorable environment for tumor cells by influencing fibroblasts, vascular endothelial cells, and tumor-associated macrophages. Together, increased HA, mainly LMW aids in CLCL progression by affecting tumor cells and microenvironment. Next, bexarotene treatment reduced the amount of total HA in murine tumor-inoculated skin and the supernatant of cultured normal human dermal fibroblasts (NHDFs) and HuT78 cells. Detailed in vitro assessments showed that bexarotene treatment decreased hyaluronic acid synthase (HAS) 1 and HAS2 expression in NHDFs and HAS1, HAS3, and CEMIP in HuT78. Chromatin immunoprecipitation assay revealed bexarotene reduced retinoid X receptor-alpha binding to the HAS1 and HAS2 promoters in NHDFs. Bexarotene potentially exerts its anti-tumor effect by reducing HA through decreased expression of HA synthase. These findings provide us with new insights into the developmental process of CLCT and additional insight into bexarotene treatment.

2024-11-01 | GSE248641 | GEO

Increased hyaluronan by naked mole-rat HAS2 extends healthspan in mice

Project description:Abundant high molecular weight hyaluronic acid (HMW-HA) contributes to cancer resistance and possibly longevity of the longest-lived rodent, the naked mole-rat1,2. To study whether the benefits of increased HMW-HA could be transferred to other animal species, we generated a transgenic mouse overexpressing naked mole-rat hyaluronic acid synthase 2 gene (nmrHAS2). nmrHAS2 mice showed increase in hyaluronan levels in several tissues, and lower incidence of spontaneous and induced cancer, extended lifespan and improved healthspan. The transcriptome signature of nmrHAS2 mice shifted towards that of longer-lived species. The most striking change observed in nmrHAS2 mice was attenuated inflammation across multiple tissues. HMW-HA reduced inflammation via several pathways including direct immunoregulatory effect on immune cells, protection from oxidative stress, and improved gut barrier function during aging. These findings demonstrate that the longevity mechanism that evolved in the naked mole-rat can be exploited to other species, and open new avenues for using HMW-HA to improve lifespan and healthspan

2023-09-08 | GSE234154 | GEO

Increased hyaluronan by naked mole-rat HAS2 improves healthspan in mice [microbiome]

2023-06-12 | GSE234286 | GEO

Increased hyaluronan by naked mole-rat HAS2 extends healthspan in mice

2023-08-10 | GSE234563 | GEO

Gene signature profiles in lung tissues of wild type mice or Has2 heterozygous deficient mice stimulated with porcine pancreatic elastase

Project description:Chronic obstructive pulmonary disease (COPD) is an inflammatory lung condition primarily caused by prolonged exposure to harmful substances, such as cigarette smoke. Hyaluronic acid synthase 2 (HAS2) synthesizes high-molecular-weight hyaluronic acid (HMW-HA), believed to have anti-inflammatory properties. Previous studies have suggested that HAS2 dysfunction may exacerbate COPD. However, the specific impact of HAS2 on pulmonary emphysema progression remains unclear. In this study, we tested the hypothesis that HAS2 dysfunction worsens airway inflammation and emphysema in mouse COPD model. Has2 heterozygous-deficient (Has2+/-) mice and their wild-type (WT) littermates have been evaluated in a porcine pancreatic elastase (PPE)-induced COPD model. Following PPE administration, Has2+/- mice exhibited a significant increase in total cell and neutrophil counts in BALF samples compared to WT mice. Has2+/- mice demonstrated enhanced emphysema development on histological analyses, with higher values of mean linear intercept relative to wild-type mice. Elastase-stimulated Has2+/- mice also demonstrated increased G-CSF level and TGF-β attenuation in lung. RNA-seq analysis suggested that PPE stimulation promotes HMW-HA synthesis and TGF-β signaling. GO analysis using Has2+/- mice-specific DEGs showed that genes associated with pathways that "negative regulation of transforming growth factor beta receptor signaling pathway" were activated after PPE administration. This study demonstrates that Has2 dysfunction exacerbates neutrophilic airway inflammation and emphysema, underscoring the protective role of HAS2 in a PPE induced emphysema model. The exacerbated response appears to involve G-CSF and TGF-β-related signaling pathways. These findings may contribute to the development of novel therapeutic strategies for COPD management.

2025-09-26 | GSE304417 | GEO

TSG-6 mediated extracellular matrix modifications regulate hypoxic-ischemic brain injury

Project description:Proteoglycans containing link-domains modify the extracellular matrix (ECM) to regulate cellular homeostasis and can also sensitize tissues/organs to injury and stress. Hypoxic-Ischemic (H-I) injury disrupts cellular homeostasis by activating inflammation and attenuating regeneration and repair pathways. In the brain, the main component of the ECM is the glycosaminoglycan (GAG), Hyaluronic Acid (HA), but whether HA modifications of the ECM regulate cellular homeostasis and response to H-I injury is not known. In this report, employing both male and female mice, we demonstrate that link-domain containing proteoglycan, TNF-stimulated gene-6 (TSG-6), is active in the brain from birth onwards and differentially modifies ECM HA during discrete neurodevelopmental windows. ECM HA modification by TSG-6 enables it to serve as a developmental switch to regulate activity of the Hippo pathway effector protein, Yes Associated Protein 1 (YAP1) in the maturing brain and in response to H-I injury. Mice that lack TSG-6 expression display dysregulated expression of YAP1 targets, excitatory amino acid transporter 1 (EAAT1; GLAST) and 2 (EAAT2; GLT-1). Dysregulation of YAP1 activation in TSG-6-/- mice coincides with age- and sex-dependent sensitization of the brain to H-I injury such that 1-week-old neonates display an anti-inflammatory response in contrast to an enhanced pro-inflammatory injury reaction in 3-month-old adult males but not females. Our findings thus support that a key regulator of age- and sex-dependent H-I injury response in the mouse brain is modulation of the Hippo-YAP1 pathway by TSG-6 dependent ECM modifications.

2024-04-09 | GSE249085 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data